NCT03272893

Brief Summary

The goal of this research project is to explore if levels of inflammation predict levels of comorbid mood disorders and treatment success in chronic pain patients. More knowledge in this respect will advance our understanding of chronic pain and comorbid syndromes, and facilitate subgroupings of patients based on the presence and/or level of low-grade inflammation. This research is an important step towards finding an explanation to why treatment effects following behavioral interventions differ across individuals, and generate new hypothesis regarding novel treatment approaches. The specific aims are: 1) to explore if baseline levels of inflammatory biomarkers predict the effects of behavioral intervention and 2) to investigate if baseline levels of inflammatory biomarkers are associated with psychological co-morbidity (e.g. depression, anxiety and fatigue) in patients with chronic pain.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 6, 2016

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

August 15, 2017

Completed
22 days until next milestone

First Posted

Study publicly available on registry

September 6, 2017

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 12, 2018

Completed
Last Updated

February 26, 2020

Status Verified

February 1, 2020

Enrollment Period

2 years

First QC Date

August 15, 2017

Last Update Submit

February 24, 2020

Conditions

Keywords

psychoneuroimmunology

Outcome Measures

Primary Outcomes (1)

  • Treatment success

    The Pain Disability Index

    At last psychological session (3 months post baseline)

Secondary Outcomes (2)

  • Comorbid psychological problems

    At first psychological session (baseline)

  • Blood biomarkers as an effect of treatment

    At last psychological session (3 months post baseline)

Other Outcomes (1)

  • Blood biomarkers as predictor for treatment success

    At first psychological session (baseline)

Interventions

The main component in the treatment is exposure to symptoms and feared situations. The iACT program is adapted from the evidence based face-to-face treatment at the Behavioral Medicine unit at Karolinska University Hospital. The iACT program has a different structure but is equal in content to face-to-face treatment, and is to be completed within ten weeks. Participants receive texts, audio files, movies and exercises and have online contact with their psychologist via an internet platform or a smart phone application. The treatment aims to encourage valued behaviors in the presence of inner discomfort.

Also known as: ACT

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The patients at the Karolinska Pain Center, suffering from chronic pain that does not respond to any other pain treatments and affects daily functioning severely.

You may qualify if:

  • Referred to a specialist clinic within pain management
  • Equal to or older than 18 years
  • Chronic pain (\> 6 months)
  • The pain is refractory
  • The pain results in significant functional limitations
  • Stable medication in the last 2 months and no planned changes in medication (except possibly discontinuation or lowering of current dose)

You may not qualify if:

  • Spontaneous improvement can be expected (without treatment)
  • Psychiatric comorbidity a) is deemed to be the main reason for the restrictions, or b) should be promptly evaluated and possibly treated, or c) may adversely affect the treatment given in the context of the study
  • Significant risk of suicide
  • Poor teamwork, defined as repeated missed appointments during the assessment / investigation phase
  • Language difficulties (Swedish)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Lasselin J, Kemani MK, Kanstrup M, Olsson GL, Axelsson J, Andreasson A, Lekander M, Wicksell RK. Low-grade inflammation may moderate the effect of behavioral treatment for chronic pain in adults. J Behav Med. 2016 Oct;39(5):916-24. doi: 10.1007/s10865-016-9769-z. Epub 2016 Jul 28.

    PMID: 27469518BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

plasma, whole blood

MeSH Terms

Conditions

Chronic PainInflammation

Interventions

Acceptance and Commitment Therapy

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPathologic Processes

Intervention Hierarchy (Ancestors)

Cognitive Behavioral TherapyBehavior TherapyPsychotherapyBehavioral Disciplines and Activities

Study Officials

  • Rikard Wicksell, PhD

    Karolinska Institutet

    PRINCIPAL INVESTIGATOR
  • Bianka Karshikoff, PhD

    Karolinska Institutet

    STUDY CHAIR
  • Linda Holmström, PhD

    Karolinska Institutet

    STUDY CHAIR
  • Mats Lekander, PhD

    Karolinska Institutet

    STUDY CHAIR
  • Jenny Åström, lic psych

    Karolinska University Hospital

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Director of Functional Area Medical Psychology, Karolinska Univ Hospital and head of research group Behavior Medicine, KI

Study Record Dates

First Submitted

August 15, 2017

First Posted

September 6, 2017

Study Start

December 6, 2016

Primary Completion

December 12, 2018

Last Updated

February 26, 2020

Record last verified: 2020-02

Data Sharing

IPD Sharing
Will not share